Programme atc- eric thervet

Programme ATC- Yannick LE MEUR


Concurrent Session: Kidney Immunosuppression: CNI Minimization – Avoidance

[129] Efficacy and Safety of Mycophenolate Mofetil (MMF)/Sirolimus (SRL) Maintenance Therapy after Calcineurin Inhibitor (CNI) Withdrawal in Renal Transplant Recipients: Final Results of the Spare-the-Nephron (STN) Trial. [130] Analysis of Allospecific T Cells in Kidney Transplant Patients on Various Immunosuppressive Protocols. [131] Cyclosporin Induces Epithelial to Mesenchymal Transition in Renal Grafts. [132] Vascular Calcineurin Inhibitor Toxicity in Early Protocol Biopsies from Human Renal Allografts. [133] Donor Marrow Infusion in Kidney Transplantation: Results of Preliminary Study. [134] Sirolimus Monotherapy in Kidney Transplantation: Results of an ITN-Sponsored Trial.

Concurrent Session: Kidney Immunosuppression: Minimization – Avoidance Protocols

[285] Extended Enrollment and Analysis of a Prospective Steroid-Free Immunosuppression Trial Supports Study Safety and Efficacy. [286] Prospective Randomized Trial of Maintenance Immunosuppression (IS) in Prednisone (P)-Free Recipients: 5-Year Results. [287] A Randomized, Open-Label Study To Compare the Efficacy and Safety of Two Different Sirolimus (SRL) Regimens with Tacrolimus (TAC) + Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients: Preliminary 2-Year Efficacy Results from the ORION Trial. [288] Long-Term Graft Survival (t½) after Rapid Discontinuation of Prednisone. [289] Successful Calcineurin-Inhibitor (CI) Discontinuation Following Early Steroid Withdrawal (ESW) in Renal Allograft Recipients; Reduced Chronic Allograft Nephropathy (CAN) and Improved Renal Function without Increased Rejection or Graft Loss. [290] A Prospective Randomized Study of Pharmacogenetic Adaptation of Tacrolimus (TAC) Treatment after Renal Transplantation.
Poster Session: Kidney Immunosuppression
[1259] A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients To Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day. [1260] NVP-AEB071 Pharmacokinetics: Effect of Metabolic Inhibition with Ketoconazole. [1261] Impact of Immunosuppressive Therapy upon Post-Transplantation Anemia: Data from the TranCept Observational Study. [1262] Cost-Effectiveness Analysis of Low Toxicity Immunosuppressive Regimens. Preliminary Results of the Quality of Life Substudy within the Symphony Study. [1263] Myfortic vs. CellCept: A Large, Single-Center Comparison. [1264] Prospective Pharmacoepidemiological Analysis of Sirolimus as Primary Immunosuppression after Kidney Transplantation in Usual Clinical Practice: Results of the ROAR™ Trial. [1265] Prospective Pharmacoepidemiological Evaluation of Sirolimus as Conversion Immunosuppression after Kidney Transplantation in Usual Clinical Practice: Results of the ROAR™ Trial. [1266] IMPDH Activity Is Correlated with the 3757T>C Polymorphism in the IMPDH Type 2 Gene in MMF Treated Kidney Transplant Patients. [1267] Immunosuppressant Regimen Based on Sirolimus Decreases Aortic Stiffness in Renal Transplant Recipients in Comparison to Cyclosporine. [1268] The Evaluation of Optimal Dose of Rituximab in ABO-Incompatible Kidney Transplantation without Splenectomy. [1269] Multi-Center Evaluation of the ARCHITECT Tacrolimus Assay. [1270] Analytical Multi-Site Evaluation of the Architect Cyclosporine Assay.

[LB01] A Protocol Biopsy Analysis from an NIH Multicenter Pediatric Renal Transplant Trial Reveals No Adverse Effect of Steroid Avoidance on the Histological Evolution of Chronic Graft Injury. [LB02] Donor-Derived Disease Transmission Events in the United States: A Report from the OPTN/UNOS Diseases Transmission Advisory Group (DTAG). [LB03] Prior Living Kidney Donors Who Were Subsequently Placed on the Waiting List: An Updated OPTN Analysis. [LB04] CNI Sparing in De Novo Renal Transplantation: 3-Year Results from the Symphony Study. [LB05] Discovering What the Eye Can't See: Gene Expression in Baseline Biopsies of Kidney Allografts. [LB06] ISA247: A Phase IIb Multicenter, Open Label, Concentration-Controlled Trial in De Novo Renal Transplantation.
Poster Session: Kidney Immunosuppression: CNI Minimization – Avoidance Protocols


[1524] A Randomized, Open-Label Study To Compare the Safety and Efficacy of Two Different Sirolimus (SRL) Regimens with Tacrolimus (TAC) + Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients: Preliminary 2-Year Safety Results from the ORION Trial. [1525] Sirolimus-Based Calcineurin Inhibitor-Sparing Immunotherapy, 6-Year Results. [1526] Renal Function with Enteric-Coated Mycophenolate Sodium in Combination with Reduced and Standard Tacrolimus Levels: Results of a 6-Month Comparative Study in De Novo Renal Transplant Recipients. [1527] Time-Dependent Analysis of Influence of Everolimus and CsA Blood Levels on the Risk of Acute Rejection after Renal Transplantation. [1528] Tacrolimus-MMF-Prednisone vs Everolimus-Low Dose Cyclosporine-Prednisone: 1 Year Results of a Prospective Clinical Trial. [1529] New Onset Diabetes Mellitus Was Lower in Enteric-Coated Mycophenolate Sodium Treated De Novo Renal Transplant Recipients with Reduced Tacrolimus Target Levels Than with Standard Tacrolimus Target Levels: Results of a 6-Month Randomized Study. [1530] Upper Everolimus Blood Levels with Very Low-Dose Cyclosporin in Renal Transplantation: 6-Month Results of the Everest Study. [1531] Predictors of Proteinuria Following Sirolimus Conversion: Analysis of a Large, Single Center Experience. - 05:00 PM [1532] Clinical Correlates of Glomerular Filtration Rate and Urinary Protein Excretion after Conversion from Tacrolimus to Sirolimus in Kidney Transplant Recipients. [1533] A Prospective Study of Steroid Free, Calcineurin Inhibitor Free Maintenance Immunosuppression Based on Rapamune/Myfortic in Kidney Transplantation. [1534] Tacrolimus (Tac)-Everolimus (EVL) Combination for Kidney Transplantation (KT): A Phase II Dose Comparison Randomized Pharmacokinetic (PK) Study. [1535] Concentration-Controlled Everolimus Is Effective and Well-Tolerated in Pediatric De Novo Renal Transplantation: Results at 12 Months. [1536] 6-Month Feasibility Study To Evaluate Replacement of Calcineurin Inhibitors (CNI) with Basiliximab in CNI-Intolerant Maintenance Kidney Transplant Recipients. [1537] Mycophenolic Acid (MPA) Adaptation over Time and Relationship between Trough and AUC in the Opticept Trial. [1538] Monitoring of Mycophenolic Acid Therapy in Renal Transplant Patients by Inosine-Monophosphate-Dehydrogenase (IMPDH) Activity. [1539] Three Years Outcome of Mycophenolate Mofetil Addition to Calcineurin-Inhibitor-Based Regimen in Kidney Transplant Recipients with Biopsy Proven Chronic Graft Dysfunction. [1540] Conversion from Calcineurin Inhibitor (CNI) Based Therapy to Sirolimus (SLR) Is Effective after Steroid Withdrawal (STW) in African American (AA) Patients with Late Renal Allograft Dysfunction. [1541] Predictors of Proteinuria in Renal Transplant Recipients Treated with Sirolimus. [1542] Comparison of Adverse Events (AEs) and Quality of Life of MMF and MPS in Long Term Kidney Transplant Recipients. A Prospective, Randomized Controlled Trial.
Poster Session: Kidney Immunosuppression: Steroid Minimization – Avoidance


[1543] Long Term Outcome of Steroid Free Maintenance Immunosuppression with Sirolimus and Low Dose Cyclosporine in Primary Kidney Transplantation. [1544] Five Year Analysis of Early Steroid Withdrawal in African-American Renal Transplant Recipients. [1545] Steroid Avoidance – Good for Most but Is There a Price To Pay? [1546] Tacrolimus-Based Immunosuppression in Renal Transplantation: Two Steroid–Free Versus Standard Regimen – A 3 Year Investigator-Initiated, Observational Follow-Up of the ATLAS Trial. [1547] Efficacy and Safety of Maintenance Neoral Monotherapy Compared to Bitherapy Neoral+ MMF or AZA in Renal Transplantation: Long Term Results. [1548] Alemtuzumab Induction with Steroid Sparing Immunosuppression in High Risk Kidney Transplantation. [1549] Rapid Steroid Withdrawal in Hispanic Renal Transplant Recipients. [1550] Early Steroid Withdrawal (Day 6) after Renal Transplantation, Long-Term Results. [1551] Prospective Randomized Multicenter Trial on Steroid Withdrawal in Pediatric Renal Transplant Recipients with Stable Graft Function under Cyclosporin A (CsA) and Mycophenolate Mofetil (MMF). [1552] Long Term Follow-Up after Early Steroid Withdrawal and Calcineurin-Inhibitor Minimization in Moderate to High Immunologic Risk Renal Transplant Recipients Including ABO Incompatible and Donor-Specific Antibody (DSA). [1553] A Case-Matched, Retrospective, Single-Center Study Comparing Low-Dose Tacrolimus/Sirolimus and Tacrolimus/MMF after Renal Transplantation with Early Steroid Withdrawal after rATG Induction. [1554] Calcineurin Inhibitor (CIN) and Mycophenolic Acid (MPA) Versus CIN and Sirolimus (SLR) in Recipients with Kidney Retransplantation: Two Year Analysis. [1555] Early Steroid Withdrawal (ESW) Versus Chronic Steroid Therapy (CST) after Retransplantation in Kidney Recipients: One Year Analysis. [1556] Weight of Numbers or Scientific Merit? — An Analysis of Steroid Withdrawal Studies at the ATC, 2006-2007. [1557] Early vs Late Steroid Withdrawal (SW) in Kidney Transplantation (KT): Metaanalysis and Metaregression of Randomized Clinical Trials (RCTs). [1558] Twenty Years of HLA-Identical Live Donor Kidney Transplantation with Early Steroid Withdrawal (ESW). [1559] Is Early Protocol Biopsy Beneficial in African American (AA) Kidney Transplant Recipients on a Steroid Avoidance Protocol (SAP)? [1560] Optimizing Immunosuppression for Elderly Kidney Transplant Recipients. [1561] Efficacy of Low Dose Thymoglobulin Induction for Renal Transplantation in the Setting of Early Steroid Withdrawal. 17h00 [1562] Influence of Cyclosporine Exposure on the Pharmacokinetics of Mycophenolic Acid in
17h00 [1563] CORRETA Trial (CORticosteroid REduction with TAcrolimus): A Prospective Brazilian
Multicenter, Randomized Trial of Early Steroid Reduction vs. Regular Steroid Dosage Maintenance on a Tacrolimus (TAC – Prograf®) and Mycophenolate Mofetil (MMF) Immunosuppression (IS) Regimen in Kidney Transplant. 17h00 [1564] Steroid Avoidance in African American Patients Undergoing Kidney Transplantation.
17h00 [1565] Early Corticosteroid Discontinuation after Kidney Transplant Does Not Deteriorate Graft

Concurrent Session: Kidney Immunosuppression: CNI Minimization/Avoidance Protocols

[526] Opticept Trial: Efficacy and Safety of Monitored MMF in Combination with CNI in Renal Transplantation at 12 Months. [527] Comparison at One Year of Interstitial Fibrosis (IF) by Automatic Quantification in Renal Transplant Recipients with Cyclosporine (CsA) Discontinuation and Sirolimus (SRL) Introduction. [528] Effects of CNI or MMF Withdrawal on Carotid Intima Media Thickness in Renal Transplant Recipients. [529] Calcineurin Inhibitor Effects on Glucose Metabolism and Endothelial Function Following Renal Transplantation. [530] Final Renal Function Outcomes from the Spare-the-Nephron (STN) Trial: Mycophenolate Mofetil (MMF)/Sirolimus (SRL) Maintenance Therapy and CNI Withdrawal in Renal Transplant Recipients. [531] Improved Outcomes after De Novo Renal Transplantation: 2-Year Results from the Symphony Study.


Mandelkorn-a doctors perspective


Tabla de contenido

DC Términos y condiciones de venta para operaciones realizas en MX VA-82560-12 Términos y Condiciones de Venta DCMX Tabla de contenido Objetivo Definir los términos y condiciones de venta para DCMX Alcance DCMX Terminología y abreviaciones DCMX: Bosch Rexroth S.A: de C.V. Responsabilidades Descripción Términos y Condiciones de Venta para operaciones

Copyright © 2010-2014 Internet pdf articles